# NextCure Inc. (NXTC)

Source: https://www.quantisnow.com/company/NXTC
Generated: 2026-11-17T15:39:01.260Z

- Ticker: NXTC
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2019
- SEC CIK: 0001661059
- Website: nextcure.com

## About

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; and NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. NextCure, Inc. has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

## Latest NXTC news and filings

- 2026-11-17 01:53 UTC [SEC Schedule 13G] [Amendment: SEC Form SCHEDULE 13G/A filed by NextCure Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-nextcure-inc-6795266)
- 2026-11-13 21:17 UTC [SEC Schedule 13G] [Amendment: SEC Form SCHEDULE 13G/A filed by NextCure Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-nextcure-inc-6790773)
- 2026-11-13 21:00 UTC [Insider Buy] [Large owner Adar1 Capital Management, Llc bought $62,897 worth of shares (12,333 units at $5.10) (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-adar1-capital-management-llc-bought-62897-worth-of-6790337)
- 2026-11-10 21:25 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by NextCure Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-nextcure-inc-6784279)
- 2026-11-10 21:15 UTC [SEC Form 8-K] [NextCure Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/nextcure-inc-filed-sec-form-8-k-results-of-operations-and-6784116)
- 2026-11-10 21:05 UTC [Earnings] [NextCure Provides Business Update and Reports Third Quarter 2026 Financial Results](https://www.quantisnow.com/insight/nextcure-provides-business-update-and-reports-third-quarter-2026-financial-6783815)
- 2026-11-09 21:19 UTC [Insider Buy] [Large owner Adar1 Capital Management, Llc bought $23,899 worth of shares (4,686 units at $5.10) (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-adar1-capital-management-llc-bought-23899-worth-of-6781573)
- 2026-11-09 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by NextCure Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-nextcure-inc-6779881)
- 2026-11-06 21:54 UTC [SEC Form 424B3] [SEC Form 424B3 filed by NextCure Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-nextcure-inc-6779415)
- 2026-11-05 23:37 UTC [SEC Form S-4] [Amendment: SEC Form S-4/A filed by NextCure Inc.](https://www.quantisnow.com/insight/amendment-sec-form-s-4a-filed-by-nextcure-inc-6777719)
- 2026-10-31 00:39 UTC [SEC Form S-4] [Amendment: SEC Form S-4/A filed by NextCure Inc.](https://www.quantisnow.com/insight/amendment-sec-form-s-4a-filed-by-nextcure-inc-6765882)
- 2026-10-30 12:00 UTC [SEC Form 8-K] [NextCure Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/nextcure-inc-filed-sec-form-8-k-leadership-update-6764627)
- 2026-10-27 23:36 UTC [Insider Buy] [Large owner Adar1 Capital Management, Llc bought $53,691 worth of shares (10,851 units at $4.95) (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-adar1-capital-management-llc-bought-53691-worth-of-6760082)
- 2026-09-30 23:36 UTC [SEC Form S-4] [Amendment: SEC Form S-4/A filed by NextCure Inc.](https://www.quantisnow.com/insight/amendment-sec-form-s-4a-filed-by-nextcure-inc-6731195)
- 2026-09-25 20:12 UTC [SEC Form 425] [SEC Form 425 filed by NextCure Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-nextcure-inc-6726453)
- 2026-09-25 20:10 UTC [SEC Form 8-K] [NextCure Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/nextcure-inc-filed-sec-form-8-k-other-events-financial-statements-6726424)
- 2026-09-03 20:10 UTC [SEC Form 8-K] [NextCure Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits](https://www.quantisnow.com/insight/nextcure-inc-filed-sec-form-8-k-entry-into-a-material-6705125)
- 2026-08-18 21:29 UTC [SEC Form S-4] [SEC Form S-4 filed by NextCure Inc.](https://www.quantisnow.com/insight/sec-form-s-4-filed-by-nextcure-inc-6687219)
- 2026-08-12 16:06 UTC [SEC Form SCHEDULE 13G filed by NextCure Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-nextcure-inc-6677436)
- 2026-08-12 15:35 UTC [SEC Form 4] [Former 10% Owner Simcere Zaiming, Inc. sold $184,800 worth of shares (30,000 units at $6.16) (SEC Form 4)](https://www.quantisnow.com/insight/former-10-owner-simcere-zaiming-inc-sold-184800-worth-of-6677413)
- 2026-08-10 20:01 UTC [SEC Form 425] [SEC Form 425 filed by NextCure Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-nextcure-inc-6673466)
- 2026-08-10 11:00 UTC [Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001](https://www.quantisnow.com/insight/avere-therapeutics-announces-500-million-private-placement-to-support-development-6672605)
- 2026-08-06 20:25 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by NextCure Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-nextcure-inc-6669477)
- 2026-08-06 20:16 UTC [SEC Form 8-K] [NextCure Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/nextcure-inc-filed-sec-form-8-k-results-of-operations-and-6669297)
- 2026-08-06 20:01 UTC [NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results](https://www.quantisnow.com/insight/nextcure-provides-business-update-and-reports-second-quarter-2026-financial-6668517)
- 2026-08-04 11:30 UTC [SEC Form 425] [SEC Form 425 filed by NextCure Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-nextcure-inc-6661078)
- 2026-08-03 21:53 UTC [Insider Buy] [Large owner Adar1 Capital Management, Llc bought $1,624,120 worth of shares (329,153 units at $4.93) (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-adar1-capital-management-llc-bought-1624120-worth-of-6660443)
- 2026-07-29 22:18 UTC [Insider Buy] [Large owner Adar1 Capital Management, Llc bought $87,713 worth of shares (17,608 units at $4.98) (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-adar1-capital-management-llc-bought-87713-worth-of-6654396)
- 2026-07-29 22:04 UTC [SEC Form 3] [New insider Adar1 Capital Management, Llc claimed ownership of 375,658 shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-adar1-capital-management-llc-claimed-ownership-of-375658-6654386)
- 2026-07-16 21:28 UTC [SEC Form 425] [SEC Form 425 filed by NextCure Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-nextcure-inc-6640187)
- 2026-07-14 11:02 UTC [SEC Form 425] [SEC Form 425 filed by NextCure Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-nextcure-inc-6636009)
- 2026-07-14 11:00 UTC [SEC Form 8-K] [NextCure Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Costs Associated with Exit or Disposal Activities, Changes in Control of Registrant, Leadership Update, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/nextcure-inc-filed-sec-form-8-k-entry-into-a-material-6636006)
- 2026-07-14 10:00 UTC [Conference Announcement] [NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy](https://www.quantisnow.com/insight/nextcure-and-avere-therapeutics-announce-merger-to-advance-once-weekly-oral-6635858)
- 2026-06-25 12:01 UTC [SEC Form 8-K] [NextCure Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits](https://www.quantisnow.com/insight/nextcure-inc-filed-sec-form-8-k-leadership-update-submission-of-6615181)
- 2026-06-22 20:14 UTC [SEC Form 4] [SEC Form 4 filed by Director Borgman Anne Elizabeth](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-borgman-anne-elizabeth-6610782)
- 2026-06-22 20:15 UTC [SEC Form 4] [SEC Form 4 filed by Director Jones Elaine V](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-jones-elaine-v-6610781)
- 2026-06-22 20:15 UTC [SEC Form 4] [SEC Form 4 filed by Director Feigal Ellen](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-feigal-ellen-6610779)
- 2026-06-22 20:14 UTC [SEC Form 4] [SEC Form 4 filed by Director Kabakoff David S](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-kabakoff-david-s-6610775)
- 2026-06-22 20:14 UTC [SEC Form 4] [SEC Form 4 filed by Director Webster Stephen W](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-webster-stephen-w-6610773)
- 2026-06-22 20:14 UTC [SEC Form 4] [SEC Form 4 filed by Director Houston John G](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-houston-john-g-6610772)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/NXTC
- Earnings history: https://www.quantisnow.com/earnings/NXTC
- Dividend history: https://www.quantisnow.com/dividends/NXTC
- Insider transactions: https://www.quantisnow.com/insiders/NXTC
- Options chain: https://www.quantisnow.com/options/NXTC
- SEC 8-K filings only: https://www.quantisnow.com/company/NXTC/8-k
- RSS and alerts for NXTC: https://www.quantisnow.com/docs/rss-feeds.md
